title: [Recommendations of the French National Health Authority for management of high blood pressure in clinical practice].
abstract: The new recommendations of the French national authority for health (or Haute Autorité de Santé: HAS) concerning management of high blood pressure (HBP) deserve to be compared with real clinical practices in a large population.
  
  
  METHODS
  [corrected] EPIMIL is a prospective epidemiological study designed to assess the prevalence of the metabolic syndrome and the risk factors in a 2045 French male military personnel coming from Paris area. The different recommendations of the HAS have been applied to these subjects, and the aim of this work is to compare these theoretical objectives to what is done in real practice.
  
  
  RESULTS
  Among these 2045 subjects aged of mean 38,6 +/- 8,8 years, 78 (4%) are known and treated for HPB. Although half of them present more than two associated risk factors, the means of systolic blood pressure and diastolic blood pressure stay at high levels. The blood pressure (BP) targets established at 140/90 mmHg are only reached by 33 patients (42%). Among the 1967 subjects considered to have normal BP, the BP considered as optimal (120/80 mmHg) is only found in 695 subjects (35.3%) and 428 (21.7%) do present ignored or neglected HBP, in spite of the presence of important associated risk factors. Then, the cardiovascular risk stratification into levels, as recommended by the HAS, shows that for these subjects considered to have normal BP, risk is finally low for 6%, moderate for 12%, and high for 3.5%.
  
  
  CONCLUSIONS
  In a selected and in theory regularly followed population, the recommendations of the HAS are insufficiently applied, as well for detection or treatment of HBP. Then, information of both medical personnel and also the interested parties should be necessary, in order to see these recommendations applied in real practice.
authors.affiliation: Service d'endocrinologie, Hôpital Bégin, Saint Mandé. lbordier@club-internet.fr
authors.forename: L
authors.initials: L
authors.lastname: Bordier
authors.forename: F
authors.initials: F
authors.lastname: Baigts
authors.forename: H
authors.initials: H
authors.lastname: Mayaudon
authors.forename: O
authors.initials: O
authors.lastname: Dupuy
authors.forename: J-P
authors.initials: JP
authors.lastname: Le Berre
authors.forename: C
authors.initials: C
authors.lastname: Garcia
authors.forename: B
authors.initials: B
authors.lastname: Bauduceau
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005602:France / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008889:Military Personnel; D009313:National Health Programs; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents